ONCAlert | Upfront Therapy for mRCC
Videos  >  

An Overview of the ALSYMPCA Study in Metastatic Prostate Cancer

Luke Nordquist, MD
Published Online:7:18 PM, Thu September 1, 2016

Luke Nordquist, MD, FACP, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, gives an overview of the Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) study, and he discusses ongoing trials examining the use of radium-223 dichloride (Xofigo) in metastatic castration-resistant prostate cancer (mCRPC).
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.